Vanessa Shih
Research Subjects
Vanessa Shih has a total of 21 co-authors. Here are the top co-authors by number of shared publications:
Amanda Harrington
Allergan plc , Irvine , CA , USA
1 shared publication- Andrew LaPrise
Verana Health, Inc., San Francisco, California
1 shared publication - Arghavan Almony
Carolina Eye Associates, Southern Pines, North Carolina; Department of Surgery, Campbell University, Lillington, North Carolina
1 shared publication Binglin Yue
Xcenda LLC , Palm Harbor , FL , USA
1 shared publicationCatherine B. McGuiness
Health Economics & Outcomes Research, Real-World Evidence, IQVIA, Plymouth Meeting, Pennsylvania
1 shared publication- Charles Clifton Wykoff
Retina Consultants of Texas, Houston, Texas
1 shared publication
Latest Publications
- Open Access
- 1 September 2021
- Published by Elsevier in Ophthalmology Glaucoma
- Vol. 4 (5) , 490-503
Clinical and Economic Burden of Glaucoma by Disease Severity
- 1 September 2021
- Published by Elsevier in Ophthalmology Glaucoma
- Vol. 4 (5) , 490-503
Open AccessClinical and Economic Burden of Glaucoma by Disease Severity
- Open Access
- 1 September 2020
- Published by Elsevier in Ophthalmology
- Vol. 127 (9) , 1179-1188
Management and Outcomes for Neovascular Age-Related Macular Degeneration
- 1 September 2020
- Published by Elsevier in Ophthalmology
- Vol. 127 (9) , 1179-1188
Open AccessManagement and Outcomes for Neovascular Age-Related Macular Degeneration
- 22 August 2019
- Published by Taylor & Francis in Current Medical Research and Opinion
- Vol. 35 (11) , 1925-1935
Healthcare resource utilization and costs among women diagnosed with uterine fibroids compared to women without uterine fibroids
Objective: To perform a retrospective, matched-cohort, longitudinal evaluation of annual pre- and post-diagnosis costs incurred among women with uterine fibroids (UF) (cases) compared to controls without UF. Methods: Data were derived from the IBM Watson Health MarketScan Commercial Claims and Encounters and Medicaid Multi-State databases. Women aged 18–64 years with ≥1 inpatient or outpatient medical claim with an initial UF diagnosis (index date) from 1 January 2010 to 31 December 2014 were included. Healthcare resource utilization (HCRU) data including pharmacy, outpatient and inpatient hospital claims were collected for 1 year pre-index and ≤5 years post-index. All-cause costs (adjusted to 2017 $US) were compared between cases and controls using multivariable regression models. Results: Analysis included 205,098 (Commercial) and 24,755 (Medicaid) case–control pairs. HCRU and total all-cause healthcare costs were higher for cases versus controls during the pre-index year and all years post-index. Total unadjusted mean all-cause costs were $1197 higher (p < .0001; Commercial) and $2813 higher (standardized difference 0.08; Medicaid) for cases during the pre-index year. Total adjusted mean all-cause costs in the first year post-index were $14,917 for cases versus $5717 for controls in the Commercial population, and $20,244 versus $10,544, respectively, in the Medicaid population. In Years 2–5 post-index, incremental mean adjusted total costs decreased, but remained significantly higher for cases versus controls at all time points in both populations (all p < .05). Conclusions: Costs were higher for women with UF compared to women without UF during the pre-index year and over 5 years post-index; differences were greatest in the first year post-index.
- 22 August 2019
- Published by Taylor & Francis in Current Medical Research and Opinion
- Vol. 35 (11) , 1925-1935
Healthcare resource utilization and costs among women diagnosed with uterine fibroids compared to women without uterine fibroids
Objective: To perform a retrospective, matched-cohort, longitudinal evaluation of annual pre- and post-diagnosis costs incurred among women with uterine fibroids (UF) (cases) compared to controls without UF. Methods: Data were derived from the IBM Watson Health MarketScan Commercial Claims and Encounters and Medicaid Multi-State databases. Women aged 18–64 years with ≥1 inpatient or outpatient medical claim with an initial UF diagnosis (index date) from 1 January 2010 to 31 December 2014 were included. Healthcare resource utilization (HCRU) data including pharmacy, outpatient and inpatient hospital claims were collected for 1 year pre-index and ≤5 years post-index. All-cause costs (adjusted to 2017 $US) were compared between cases and controls using multivariable regression models. Results: Analysis included 205,098 (Commercial) and 24,755 (Medicaid) case–control pairs. HCRU and total all-cause healthcare costs were higher for cases versus controls during the pre-index year and all years post-index. Total unadjusted mean all-cause costs were $1197 higher (p < .0001; Commercial) and $2813 higher (standardized difference 0.08; Medicaid) for cases during the pre-index year. Total adjusted mean all-cause costs in the first year post-index were $14,917 for cases versus $5717 for controls in the Commercial population, and $20,244 versus $10,544, respectively, in the Medicaid population. In Years 2–5 post-index, incremental mean adjusted total costs decreased, but remained significantly higher for cases versus controls at all time points in both populations (all p < .05). Conclusions: Costs were higher for women with UF compared to women without UF during the pre-index year and over 5 years post-index; differences were greatest in the first year post-index.